PICO
및
근거표

| Outcome or subgroup title                                  | No. of studies | No. of participants | Statistical method                | Effect size                  |
| :--------------------------------------------------------- | :------------- | :------------------ | :-------------------------------- | :--------------------------- |
| 18 No of subjects, and nature of, early adverse effects    | 1              |                     | Odds Ratio (M-H, Fixed, 95% CI)   | Subtotals only               |
| 18.1 COPD                                                  | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 0.66 [0.30, 1.48]            |
| 18.2 Dyspnea                                               | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 1.81 [0.60, 5.41]            |
| 18.3 Pharyngitis                                           | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 1.00 [0.35, 2.86]            |
| 18.4 Flu syndrome                                          | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 0.62 [0.20, 1.91]            |
| 18.5 Rhinitis                                              | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 1.50 [0.42, 5.34]            |
| 18.6 Bronchitis                                            | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 2.01 [0.50, 8.05]            |
| 18.7 Increased cough                                       | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 0.60 [0.14, 2.51]            |
| 18.8 Myalgia                                               | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 2.51 [0.49, 12.96]           |
| 18.9 Increased sputum                                      | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 0.75 [0.17, 3.36]            |
| 18.10 Pneumonia                                            | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 2.01 [0.37, 10.97]           |
| 18.11 Asthenia                                             | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 2.01 [0.37, 10.97]           |
| 18.12 Guillain - Barre syndrome                            | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 0.33 [0.01, 8.19]            |
| 18.13 Other                                                | 1              | 2215                | Odds Ratio (M-H, Fixed, 95% CI)   | 0.49 [0.26, 0.92]            |
| 19 Patients with late adverse effects                      | 2              | 2244                | Peto Odds Ratio (Peto, Fixed, 95% CI) | 2.33 [1.22, 4.46]            |
| 20 Mortality                                               | 1              |                     | Odds Ratio (M-H, Fixed, 95% CI)   | Totals not selected          |

## 12) 폐렴구균 백신은 모든 COPD 환자에게 접종해야 한다(근거수준: 낮음, 권고강도: 약함).

### 근거표 12: Pneumococcal vaccine

| 연구수 | 연구설계           | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :----------------- | :---------- | :------- | :------- | :------- | :---------- | :------- |
| 1      | 무작위대조군연구 1개 | 없음        | 있음     | 없음     | 있음     | 없음        | 낮음     |

Author/Title/Reference/Yr: Leech JA, Gervais A, Ruben FL, 1987, "Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease", Canadian Medical Association Journal, vol. 136, no. 4, pp. 361-365. Ref ID: 1620
N=: N= 189 (N=92 experimental group) (N=97 control group). Location=(Montreal) Sites=(1 site). Data collected 1981.
Duration=: (2 years- 6 month interval follow-ups)
Research Design: Double blind RCT
Aim: To demonstrate a protective role of polyvalent pneumococcal vaccine in severe COPD.
Operational Definition: No operational definition of COPD reported. Clinical diagnosis of COPD and an FEV1 <1.5 L
Definitions given for:
- Upper respiratory tract infection: presence of runny nose; fever; increased cough without an increase in the quantity or a change in the color of the sputum.
- Lower respiratory tract infection: a combination of fever, increased cough and a change in the color of the sputum quantity.
- Pneumonia: Presence of symptoms of a lower respiratory tract infection and infiltrate on a chest roentogram.
Population: Stable, ambulatory population attending chest clinic with "severe COPD": COPD diagnosis (including chronic bronchitis and emphysema but not asthma, cystic fibrosis or bronchiectasis) FEV1<1.5 L Previous pneumococcal vaccine excluded
Interventions and Comparisons: N=92 Influenza vaccine & 14-valent pneumococcal polysaccharide vaccine by injection
N=97 Influenza vaccine & saline placebo by injection
Outcomes: Death rate/Hospital admissions/Emergency visits/Mean length of hospital stay
Characteristics: Mean age control group/experimental group=69/66 yrs. Age range 40 to 89 years.
Men control group/experimental group=69/66
FEV1/FVC in control group=0.96/2.13 L FEV1/FVC in experimental group=0.94/2.18 L
Mean FEV1 predicted 75%/Mean FEV/FVC 63%

<PAGE>145